(Q34129930)

English

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

scientific article published on August 5, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (English)

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Isamu Okamoto

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Hiroyasu Kaneda

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Taroh Satoh

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Wataru Okamoto

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Masaki Miyazaki

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ryotaro Morinaga

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Shinya Ueda

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Masaaki Terashima

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Asuka Tsuya

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Akiko Sarashina

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Koichi Konishi

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Tokuzo Arao

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kazuto Nishio

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Rolf Kaiser

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kazuhiko Nakagawa

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20688946

17 June 2024

publication date

5 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

full work available at URL

https://aacrjournals.org/mct/article-pdf/9/10/2825/2332850/2825.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688946

17 June 2024

http://intl-mct.aacrjournals.org/cgi/content/abstract/9/10/2825

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688946

17 June 2024

https://aacrjournals.org/mct/article-pdf/9/10/2825/2332850/2825.pdf

Portable Document Format

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

https://aacrjournals.org/mct/article-pdf/9/10/2825/2332850/2825.pdf

Portable Document Format

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2825-2833

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies

1

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Clinical translation of angiogenesis inhibitors

2

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

3

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

4

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Clinical biomarkers of angiogenesis inhibition

5

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

6

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation

7

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

8

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

9

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).

10

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

11

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

12

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

13

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

16

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

17

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

18

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

19

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

20

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Modelling the role of angiogenesis and vasculogenesis in solid tumour growth.

21

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Translational physiology: origin and phenotype of lung side population cells.

22

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)

23

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Origin of endothelial progenitors in human postnatal bone marrow

24

1 reference

10.1158/1535-7163.MCT-10-0379

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0379

17 June 2024

Identifiers

10.1158/1535-7163.MCT-10-0379

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34129930&oldid=2182195990"